OncoCyte Corp | Business Contracts

Consulting Agreement, by and between the Company and Douglas Ross, dated as of December 16, 2022 (Filed With SEC on December 21, 2022)

Stock Purchase Agreement, dated December 15, 2022, by and among Dragon Scientific, LLC, Oncocyte Corporation and Razor Genomics Inc (Filed With SEC on December 21, 2022)

Description of Securities (Filed With SEC on March 11, 2022)

Collaboration Agreement, dated January 13, 2022, by and between Oncocyte Corporation and Life Technologies Corporation (Filed With SEC on March 11, 2022)

Agreement and Plan of Merger dated February 2, 2021, amended February 23, 2021, and amended and restated as of April 15, 2021, by and among OncoCyte Corporation, CNI Monitor Sub,... (Filed With SEC on April 19, 2021)

Amended and Restated Exclusive License Agreement, effective February 15, 2018, between Razor Genomics, Inc. and the licensor named therein (Filed With SEC on March 19, 2021)

Lease Agreement, dated November 10, 2011, between Insight Genetics, Inc. and MPC Holdings, LLC, as renewed by notice dated January 3, 2019 (Filed With SEC on March 26, 2020)

Separation Agreement and General Release of All Claims, by and between the Company and Douglas Ross, dated December 16, 2022 (Filed With SEC on December 21, 2022)

Separation Agreement and General Release of All Claims, by and between the Company and Gisela Paulsen, dated December 16, 2022 (Filed With SEC on December 21, 2022)

Amended & Restated Change in Control and Executive Severance Plan Agreement, by and between the Company and Joshua Riggs, effective as of December 2, 2022 (Filed With SEC on December 5, 2022)

Employment Agreement, by and between the Company and Joshua Riggs, effective as of December 2, 2022 (Filed With SEC on December 5, 2022)

Consulting Agreement, by and between the Company and Ronald Andrews, dated as of December 1, 2022 (Filed With SEC on December 5, 2022)

Separation Agreement and General Release of All Claims, by and between the Company and Ronald Andrews, dated December 1, 2022 (Filed With SEC on December 5, 2022)

Form of Warrant (Filed With SEC on April 19, 2022)

Underwriting Agreement, dated April 13, 2022, between Oncocyte Corporation and BTIG, LLC, as representative of the underwriters named therein (Filed With SEC on April 19, 2022)

Form of Securities Purchase Agreement, among us and certain investors, dated April 13, 2022 (Filed With SEC on April 13, 2022)

Addendum No. 2 to Exclusive Sublicense Agreement in the PRC Territory, dated December 5, 2021, by and among Razor Genomics, Inc., Oncocyte Corporation, Encore Clinical, Inc., and... (Filed With SEC on December 8, 2021)

Change in Control and Executive Severance Plan Agreement, dated October 4 2021, between Oncocyte Corporation and Gisela Paulsen (Filed With SEC on October 7, 2021)

Amendment of 2018 Equity Incentive Plan (Filed With SEC on June 28, 2021)

At-The-Market Sales Agreement, dated June 11, 2021, between OncoCyte Corporation and BTIG, LLC (Filed With SEC on June 14, 2021)

Description of Securities (Filed With SEC on March 19, 2021)

Purchase Agreement, dated February 4, 2021, between OncoCyte Corporation and Piper Sandler & Co., as representative of the underwriters named therein (Filed With SEC on February 5, 2021)

Agreement and Plan of Merger, dated as of February 2, 2021, among Oncocyte Corporation, CNI Monitor Sub, Inc., Chronix Biomedical, Inc., the Shareholders who became a Party to the... (Filed With SEC on February 3, 2021)

Subscription Agreements, dated January 20, 2021, between OncoCyte Corporation and the investors named therein (Filed With SEC on January 21, 2021)

Exclusive Sublicense Agreement in the PRC Territory (Filed With SEC on December 16, 2020)

Reduction in Salary Agreement between OncoCyte Corporation and Tony Kalajian (Filed With SEC on September 28, 2020)

Reduction in Salary Agreement between OncoCyte Corporation and Lyndal Hesterberg (Filed With SEC on September 28, 2020)

Reduction in Salary Agreement between OncoCyte Corporation and Albert Parker (Filed With SEC on September 28, 2020)

Employment Agreement, dated March 23, 2020, between OncoCyte Corporation and Douglas Ross (Filed With SEC on July 29, 2020)

Acknowledgement and Agreement, dated May 7, 2020, between OncoCyte Corporation and Lyndal Hesterberg (Filed With SEC on May 12, 2020)

Acknowledgement and Agreement, dated May 7, 2020, between OncoCyte Corporation and Mitchell Levine (Filed With SEC on May 12, 2020)

Acknowledgement and Agreement, dated May 7, 2020, between OncoCyte Corporation and Ronald Andrews (Filed With SEC on May 12, 2020)

Loan Deferral Agreement, dated April 2, 2020, between OncoCyte Corporation and Silicon Valley Bank (Filed With SEC on May 12, 2020)

U.S. Small Business Administration Paycheck Protection Program Note (Filed With SEC on April 29, 2020)

Form of Subscription Agreements, dated April 24, 2020, between OncoCyte Corporation and the investors named therein (Filed With SEC on April 28, 2020)

Oncocyte Corporation Change in Control and Severance Plan (Filed With SEC on March 26, 2020)

Description of Securities (Filed With SEC on March 26, 2020)

(Filed With SEC on March 26, 2020)

Employment Agreement, dated May 22, 2019, between OncoCyte Corporation and Padma Sundar (Filed With SEC on March 26, 2020)

Form of Change in Control and Severance Agreement (Filed With SEC on March 26, 2020)

Equity Distribution Agreement, dated March 20, 2020 (Filed With SEC on March 20, 2020)

Agreement and Plan of Merger, dated as of January 10, 2020, among Oncocyte Corporation, Cancer DX Sub, Inc., Insight Genetics, Inc., the Shareholders who became a Party to the... (Filed With SEC on February 5, 2020)

Subscription Agreement, dated January 2, 2020, between Oncocyte Corporation and the investors named therein (Filed With SEC on January 6, 2020)

Office Lease Agreement, dated December 23, 2019, between OncoCyte Corporation and Cushing Ventures, LLC (Filed With SEC on December 27, 2019)

Form of Subscription Agreement between OncoCyte Corporation and the investors party thereto (Filed With SEC on November 14, 2019)

Warrant to Purchase Common Stock, dated October 17, 2019, between OncoCyte Corporation and Silicon Valley Bank (Filed With SEC on October 21, 2019)

First Amendment to Loan and Security Agreement, dated October 17, 2019, between OncoCyte Corporation and Silicon Valley Bank (Filed With SEC on October 21, 2019)

Warrant to Purchase Shares of Common Stock, dated August 1, 2019 (Filed With SEC on August 14, 2019)

Transition Agreement, dated July 1, 2019, between OncoCyte Corporation and William Annett (Filed With SEC on July 8, 2019)

Employment Agreement, dated June 4, 2019, between OncoCyte Corporation and Ronald Andrews (Filed With SEC on June 6, 2019)

Separation Agreement, dated January 22, 2019, between OncoCyte Corporation and Kristine Mechem (Filed With SEC on April 1, 2019)

Purchase Agreement between OncoCyte Corporation and Piper Jaffray & Co. dated February 8, 2019 (Filed With SEC on February 12, 2019)

OncoCyte Corp (52)